Company intelligence / Profile preview

Nordic Pharma

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

Nordic Pharma has launched several specialized pharmaceutical products globally, including the recent commercial launch of Lacrifill® Canalicular Gel for dry eye disease in both Europe and the U.S. The product is FDA-cleared and CE-marked based on pivotal clinical studies demonstrating efficacy in temporarily blocking tear drainage to treat dry eye symptoms. The company maintains a portfolio across women’s health, rheumatology, ophthalmology, critical care, and other specialty areas.[1][2][3][4]

Therapeutic areas: OtherRheumatologyOphthalmologyWomen's Health
Modalities: Small moleculesBiotechnology-derived medicinesHyaluronic acid derivatives[4][5]
Industry: Biotech

Partnerships

Collaborates with global biopharmaceutical companies to bring biotechnology-derived medicines to market.[5]

Beyond the preview

Go deeper on Nordic Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nordic Pharma.

Explore the full profile